Class action lawsuit filed against Aardvark Therapeutics over IPO claims
News provided byAardvark Therapeutics, Inc · 1 min read
New York, New York, Bronstein, Gewirtz & Grossman, LLC, a well-known investor rights law firm, has filed a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers on behalf of investors who purchased the company's securities between February 13, 2025, and May 14, 2026.
The lawsuit alleges that Aardvark Therapeutics and its officers violated federal securities laws by issuing misleading information in connection with the company's initial public offering (IPO) in February 2025. Specifically, the complaint states that the registration statement and prospectus were negligently prepared, containing untrue statements of material fact or omitting necessary facts that made the statements misleading. Additionally, the lawsuit claims that the company's public statements during the class period were materially false and misleading, overstating the safety and prospects of ARD-101, the company’s key drug candidate.
The case was filed against Aardvark Therapeutics, Inc., and named officers, as well as former officers and directors, who are alleged to have been involved in the preparation and dissemination of the misleading information. According to the complaint, the false statements about ARD-101’s safety and its clinical, regulatory, and commercial prospects were made to mislead investors.
Bronstein, Gewirtz & Grossman, LLC, notes that any investor who suffered a loss in Aardvark securities and wishes to participate in the lawsuit must act by October 13, 2026. Participation does not require serving as the lead plaintiff, and the firm represents investors on a contingency fee basis, meaning it will seek reimbursement for out-of-pocket expenses and attorneys' fees only if it is successful in the lawsuit.
The firm emphasizes its commitment to restoring investor capital and ensuring corporate accountability, stating, "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, the founding partner of Bronstein, Gewirtz & Grossman, LLC.
For updates on the case, investors can follow the firm on social media platforms such as LinkedIn, X (formerly Twitter), Facebook, and Instagram.